Most of the world’s pharmaceutical supply originates from a handful of countries, with China and India dominating the production of raw drug ingredients while the United States and Europe lead in finished brand-name drugs and advanced biologics. The split depends on what part of the supply chain you’re looking at, because a pill sold at your local pharmacy may have crossed several continents before reaching the shelf.
Where Raw Drug Ingredients Come From
The active pharmaceutical ingredient, or API, is the chemical compound in a drug that actually treats your condition. Everything else in a pill (fillers, coatings, binders) is inactive. And the production of these active ingredients is heavily concentrated in two countries.
India holds about 43% of all active API drug master files globally, with China close behind at roughly 18% of total filings but surging fast. In 2024, China actually overtook India in new annual filings, capturing 45% of that year’s submissions. Together, the two countries account for the majority of the world’s capacity to produce the chemical building blocks of medicine. This means that even drugs “made in America” or “made in Germany” often rely on raw materials shipped from factories in Gujarat, Hyderabad, Shanghai, or Zhejiang province.
Where Finished Drugs Are Made
Turning a raw ingredient into a tablet, capsule, or injectable you can actually use requires a second stage of manufacturing. Here the picture shifts. The United States still has significant capacity for finished drug production, but more than half of its supply comes from overseas. A 2022 analysis by the U.S. Government Accountability Office found that 58% of the roughly 4,800 manufacturing establishments supplying the American market were located in foreign countries.
For generic drugs specifically, the foreign dependence is even steeper. The U.S. outsources 78% of its solid oral generics (the everyday tablets and capsules most people take) and nearly 60% of its injectable generics. Even for brand-name drugs, about half of solid oral forms and 55% of injectables are produced abroad. India is the world’s largest generic drug exporter, sometimes called “the pharmacy of the world,” supplying affordable versions of medications to the U.S., Africa, and dozens of other markets.
Biologics Tell a Different Story
Biologics are a newer, more complex class of drugs. Think insulin, monoclonal antibodies for cancer, and vaccines. These are made from living cells rather than chemical synthesis, and they require highly specialized facilities. The geography of biologics manufacturing looks nothing like the API landscape.
Global biopharmaceutical manufacturing capacity totals over 16.5 million liters across more than 1,500 facilities worldwide. The United States and Canada hold about 37% of that capacity (around 6 million liters, with 5.6 million in the U.S. alone). Western Europe accounts for 33%, roughly 5.5 million liters. The entire Asia-Pacific region, including China and India, holds about 25%. China and India each contribute less than a million liters of biologics capacity.
Biosimilars, the generic equivalents of biologics, tilt more toward Asia. Of the 193 facilities involved in biosimilar manufacturing globally, 117 are located in Asia. But in terms of total biologics volume, the Western world still dominates.
Why Production Shifted Overseas
Pharmaceutical manufacturing didn’t always look this way. Through the 1990s, the U.S. and Europe produced far more of their own drug supply. Several forces drove production offshore. Lower labor costs in India and China made API synthesis and generic drug manufacturing dramatically cheaper. Environmental regulations in the U.S. and Europe added costs that manufacturers in Asia could avoid. And as global trade barriers dropped, it became easier and more profitable to source ingredients from wherever they were cheapest.
The result is a supply chain that’s efficient but fragile. When a single factory in China shuts down due to an environmental inspection or a pandemic lockdown, it can ripple through to drug shortages in American hospitals. The COVID-19 pandemic made this vulnerability visible to the public for the first time, but health policy experts had been raising alarms for years.
The Push to Bring Manufacturing Back
Reducing foreign dependence on pharmaceutical manufacturing has become a bipartisan priority in the United States. In May 2025, the Trump administration issued an executive order directing the FDA and EPA to streamline permitting and inspection processes for domestic pharmaceutical facilities. Some policymakers have also proposed pharmaceutical tariffs to make foreign-produced drugs less cost-competitive with domestic alternatives.
Policy analysts at the Center for Strategic and International Studies caution that tariffs and executive orders alone won’t solve the problem. The deeper challenges include lengthy permitting delays, a shortage of trained manufacturing workers, and tax structures that don’t favor domestic production. CSIS has suggested that a model similar to the CHIPS Act, which used direct subsidies, tax incentives, and workforce development programs to rebuild U.S. semiconductor manufacturing, could be more effective for pharmaceuticals.
Europe faces a similar situation. The EU currently offers up to 10 years of data and market protection for new medicines, with an additional year for significant therapeutic innovations, partly to incentivize keeping production on the continent.
A Quick Geographic Breakdown
- China: The largest and fastest-growing source of raw drug ingredients (APIs), especially for antibiotics, vitamins, and basic chemical compounds.
- India: The world’s top generic drug manufacturer and a major API producer, supplying affordable medications globally.
- United States: Leads in biologics manufacturing capacity and remains a major producer of brand-name drugs, but imports the majority of its generic supply.
- Western Europe: Strong in both biologics and innovative brand-name drugs, with major production hubs in Ireland, Switzerland, Germany, and Belgium.
- Ireland: Punches well above its weight due to favorable tax policies that attract multinational pharma companies to set up manufacturing there.
The short answer is that no single country makes “most” pharmaceuticals. China and India produce the bulk of the raw ingredients. India leads in generic finished drugs. The U.S. and Europe lead in biologics and innovative therapies. Your medication likely touched at least two or three countries before it reached you.